Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
暂无分享,去创建一个
D. Ho | M. Markowitz | H. Mo | K. Appelt | S. Webber | V. Kalish | A. Patick | S. Reich | B. Wu | M Markowitz | S. Webber | L. Musick | S. Kaldor | H Mo | V Kalish | K Appelt | B Wu | A K Patick | L Musick | S Kaldor | S Reich | D Ho | S Webber | Bo-Wen Wu
[1] B. Ho,et al. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.
[2] W. Farmerie,et al. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. , 1990, The Journal of biological chemistry.
[3] B. Moss,et al. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Kosa,et al. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease , 1996, Antimicrobial agents and chemotherapy.
[5] D. Richman. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents , 1993, Antimicrobial Agents and Chemotherapy.
[6] J. Barrish,et al. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease , 1995, Antimicrobial agents and chemotherapy.
[7] DMP450, a new cyclic urea inhibitor of HIV protease with potent in vitro antiviral activity , 1995 .
[8] D Norbeck,et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.
[9] J. Barrish,et al. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor , 1995, Journal of virology.
[10] P. Lam,et al. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor , 1993, Antimicrobial Agents and Chemotherapy.
[11] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[12] Tomi K. Sawyer,et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.
[13] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[14] J S Mills,et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.
[15] I B Duncan,et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.
[16] H. Okayama,et al. High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.
[17] D A Scudiero,et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.
[18] D. Lambert,et al. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells , 1992, Antimicrobial Agents and Chemotherapy.
[19] C. Debouck,et al. The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.
[20] J. Robinson,et al. PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. , 1992, Virology.
[21] L. Everitt,et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Ogden,et al. High-level expression of self-processed HIV-1 protease in Escherichia coli using a synthetic gene. , 1989, Biochemical and biophysical research communications.
[23] P. Darke,et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[24] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[25] J F Morrison,et al. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.
[26] A. Wlodawer,et al. Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.
[27] E A Emini,et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.
[28] M. Kuroda,et al. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor , 1994, Journal of virology.
[29] P. Jadhav,et al. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Ho,et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.
[31] A. Kaplan,et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles , 1993, Journal of virology.
[32] H. Gendelman,et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.